InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
carldfw Free
10/13/21 8:04 PM
profile icon
carldfw Free
10/07/21 8:19 AM
profile icon
Hokane Free
10/06/21 3:25 AM
profile icon
carldfw Free
07/05/21 6:36 PM
profile icon
lowfloatwayne Terminated
04/08/20 6:34 PM
profile icon
lowfloatwayne Terminated
01/29/20 1:31 PM
profile icon
makinezmoney Free
01/29/20 12:30 PM
profile icon
carldfw Free
03/29/19 6:03 PM
profile icon
carldfw Free
02/27/19 6:30 PM
profile icon
lowfloatwayne Terminated
02/22/19 9:58 PM
profile icon
carldfw Free
02/22/19 8:07 AM
profile icon
Spike1976 Free
02/21/19 4:40 PM
profile icon
Garyst Free
01/27/19 3:25 PM
profile icon
lowfloatwayne Terminated
01/26/19 8:21 PM
profile icon
carldfw Free
01/23/19 8:05 AM
profile icon
Garyst Free
12/19/18 3:29 PM
profile icon
carldfw Free
12/19/18 5:40 AM
profile icon
Garyst Free
12/18/18 10:05 PM
profile icon
carldfw Free
12/18/18 8:05 PM
profile icon
lowfloatwayne Terminated
10/10/18 12:04 PM
profile icon
carldfw Free
09/07/18 10:12 AM
profile icon
Garyst Free
09/06/18 9:32 PM
profile icon
carldfw Free
09/06/18 9:28 PM
profile icon
Garyst Free
08/22/18 1:32 PM
profile icon
carldfw Free
08/21/18 9:07 PM
profile icon
Garyst Free
08/13/18 9:25 AM
profile icon
carldfw Free
08/11/18 11:10 PM
profile icon
Garyst Free
08/10/18 11:43 AM
profile icon
carldfw Free
08/09/18 10:03 PM
profile icon
Garyst Free
05/23/18 9:27 PM
profile icon
Stockhunter469 Free
05/14/18 10:55 AM
profile icon
Garyst Free
05/13/18 10:25 PM
profile icon
Garyst Free
05/11/18 10:05 PM
profile icon
bullofthewest Free
05/11/18 5:26 PM
profile icon
Garyst Free
05/10/18 2:35 PM
profile icon
Garyst Free
05/10/18 11:49 AM
profile icon
bullofthewest Free
05/09/18 8:35 PM
profile icon
Garyst Free
05/09/18 8:26 PM
profile icon
Garyst Free
05/09/18 1:17 PM
profile icon
Garyst Free
05/08/18 4:02 PM
profile icon
Garyst Free
05/08/18 3:09 PM

Acusphere, Inc (ACUS) RSS Feed

Followers
26
Posters
122
Posts (Today)
0
Posts (Total)
1000
Created
04/07/07
Type
Free
Moderators


Update 01.20.2011

Today : Friday 20 January 2012

Acusphere, Inc. (ACUS.PK) today announced that its stockholders voted to approve the proposed 1-for-10 reverse stock split of the Company's common stock at its Special Meeting of Stockholders held today. 

See post 749 for press release, also currently a sticky post.

End Update 01.20.2012



Update 12.23.2011

Proxy Notice Of Special Meeting Received via US Mail.  Posted a sticky on some highlights, I can't find a link to it on the ACUS website but one can likely find it searching the SEC, maybe?

They are asking for a 1-10 reverse stock split.  The proxy has lots of interesting stuff in it.  Maybe someone can find a link to it and post it.......

End Update 12.23.2011


Update 12.20.2011

Another Letter to the Shareholders was issued yesterday and can be read as the first sticky post.

A line from the letter is:

"We have now arrived at an important juncture, and we need your support to help effect a reverse stock split to allow the Company to finance the completion of our strategic direction."

So a reverse split may be coming.  I have lightened up on my own shares but as of now still hold some and may buy or sell more as the future unfolds.

End 12.20.2011 update.



Update 10.07.2011

Imagify was shot down by the FDA advisory panel a couple years ago ,give or take a little, I think it was 16-1, mainly because Imagify had not been tested against a placebo.  They had run trials against the "Standard Of Care," Nuke testing.

On June 8th 2011 ACUS announced that Imagify has been granted a SPA by the FDA for an addtional phase III against a placebo.

Also on June 8th  2011 ACUS announced that they hoped to complete their work to the EU for an MMA application for Imagify in the 2nd half of 2011.

You can read about these latest developments here, and I will try to figure out how to make this post a sticky.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64007218

Since I-Hub did away with their spell checker I no longer run my posts through one, so I apoligize to those who may be offened by this fact, in advance.

End of 10.07.2011 update.



Imagify-

Description:Imagify is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States & Europe.

Partnership Agreement : On October 24, 2008, Acusphere, Inc. (the "Company") announced the signing of a definitive agreement with Cephalon, Inc. ("Cephalon") to provide $20 million in upfront financing by purchasing a $15 million senior secured convertible note and by paying a $5 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage injectable formulation of celecoxib using Acusphere's proprietary Hydrophobic Drug Delivery System (HDDS?) technology.   On July 7, 2004, Acusphere announced a $70 million partnership for European development and marketing rights to Nycomed. From this partnership, Acusphere has currently received $12 million in milestone payments. An additional $58 million in milestone payments are related to regulatory approvals and achievement of certain sales goals.

Market Potential & Competition : The potential market in the US for Imagify is estimated to be roughly $2 billion annually. It is estimated that more than 10 million procedures are done each year in the U.S. to detect coronary artery disease. The leading procedure to detect coronary heart disease is nuclear stress testing, which costs roughly double the amount to implement, takes significantly more time to administer, and is arguably more harmful to the patient/environment.

FDA response : The FDA granted ACUS an Advisory Panel Meeting for Imagify on December 10th, 2008.  The panel voted against recommendation by a vote of 16-1.  The PDUFA date is set for February 28, 2009. On this date the FDA will decide whether or not they approve of the drug.  The company is also working with Nycomed to submit its MAA filing in Europe.

AI-850-
Description: AI-850 is a Phase 1 clinical trial completed product candidate that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer drug.
On March 31, Acusphere licensed the property rights to its Hydrophobic Drug Delivery System™ (HDDS) for oncology applications to Cephalon for $10 million. Per the last conference call, the company may choose to license out the HDDS system to other companies for other applications. (Oncology is only one of the potential applications.)

If you would like to listen to Acusphere's most current conference calls or presentations, please go to the following:
http://investor.acusphere.com/events.cfm

Current share count:

Authorized Common Stock: 250 million shares
Outstanding Common Stock: 49.51 million shares
Preferred Stock convertible to common: 25.2 million shares

Acusphere, Inc., a specialty pharmaceutical company, develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States. Its porous microparticle technology enables to control the size and porosity of particles, including nanoparticles and microparticles. The company develops products in the areas of cardiology, oncology, and asthma. Its lead product candidate Imagify, a cardiovascular drug, is in Phase 3 clinical development for the detection of coronary artery disease. The company?s products also include AI-850, a Phase 1 clinical trial completed product candidate that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer drug; AI-128, a Phase 1 clinical study completed formulation of asthma drug. Acusphere was founded in 1993 and is headquartered in Watertown, Massachusetts.

http://www.acusphere.com/

http://finance.yahoo.com/q/h?s=ACUSD.pk





 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
ACUS Latest News
  • No Recent News Available for this company!
New Post